A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

Inclusion criteria:

- Must have diagnosis of relapsed or refractory multiple.

- bone marrow function [ANC (absolute neutrophil count) greater than 1000/mm3];
platelet count greater than or equal to 75,000/mm3.

- renal function (calculated creatinine clearance >50 mL.min, albumin less than or
equal to 500 mg).

Exclusion criteria:

- Failed more than 3 prior lines of therapy including stem cell transplant.

- Females who are pregnant or nursing.

- Unstable blood pressure.

- Significant heart conditions or history of thrombosis.

- Any unstable, pre-existing major medical condition or history of other cancers.

- Have received an investigational drug, chemotherapy, radiation treatment or surgery
within 28 days prior to entering the study.